Background: Intravenous iron polymaltose (IPM) is commonly utilised in pregnancy when oral treatment is not tolerated or where rapid replenishment of iron stores is required, but data on use in pregnancy is scarce.
INTRODUCTION
Iron deficiency represents the most widespread nutritional deficiency globally and is the leading cause of anaemia during pregnancy. 1 Anaemia is estimated to affect 38% of pregnancies worldwide and is associated with a significantly increased risk of perinatal morbidity and mortality. 1,2 Improvements in haematological status during pregnancy are associated with reduced risk
Use evaluation
Women were initially classified according to the presence or absence of anaemia at the time of IV IPM infusion (haemoglobin < 105 g/L after the first trimester 7 ), then further classified according to the severity of anaemia, either mild (haemoglobin 100-104 g/L), moderate (haemoglobin 90-99 g/L) or severe (haemoglobin < 90 g/L). The presence of iron deficiency was determined according to a serum ferritin < 30 μg/L or transferrin saturation ≤16%. 8 The dose of IPM prescribed was compared to that recommended by the local hospital guideline, which recommends calculating the dose based on the following equation:
Iron Dose = Weight × (Target haemoglobin − Current haemoglobin) × 0.24 + 500 mg. 9 The guideline recommends a target haemoglobin of 150 g/L, but it does not specify which weight to use when calculating the dose (ie whether to use pre-pregnancy or current weight). In order to evaluate the appropriateness of prescribed iron doses, the expected IV iron dose was first calculated based on the woman's haemoglobin deficit and current weight. To allow for rounding and minor variation in dosing weights, 200 mg was subtracted from this expected value. This figure was then compared with the actual dose prescribed. Based on this comparison the doses were then classified as being either 'At Recommended Dose' or 'Below Recommended Dose'.
Safety measures
Adverse drug reactions (ADRs) were classified as either local reactions, occurring at or near the injection site, or systemic reactions which include any other reactions regardless of severity.
Documentation of infusion rate modification, infusion termination or any medications used to manage reactions in the case notes were used to assess the impact of the experienced ADR.
Significance of reactions leading to infusion termination were further analysed based on recommencement status: infusions recommenced on the same or an alternate day and infusions that were completely ceased.
Efficacy measures
Response to IV iron was evaluated by exploring changes in haemoglobin from immediately prior to IV iron infusion to 2-4 weeks post-treatment, and immediately prior to delivery. Women were classified as having treatment success if they had a haemoglobin increase of 20 g/L during the relevant time period. Anaemia status at 2-4 weeks post-infusion and immediately prior to delivery were also examined. Efficacy of IV iron based on changes in haemoglobin was examined only among those women with confirmed IDA. 
Statistical analysis

RESULTS
IV iron use
Following linkage of the pharmacy dispensing records and perinatal statistics database, a total of 247 women were identified as receiving IV iron. We then excluded 34 women, 31 who re- Compared to non-anaemic iron-deficient women, a lower proportion of anaemic women were Caucasian (66% vs 82%; P = 0.04).
Anaemic women also had a later booking gestation (16.8 weeks vs
14.3; P = 0.005) and were more likely to have trialled oral iron therapy prior to IV iron treatment (82% vs 59%; P < 0.001) ( Table 1) .
Mean gestation at treatment was 33.5 weeks and 32.6 weeks for the IDA and non-anaemia iron deficiency groups. The median 
Safety
Overall, 50/213 women (23.5%) experienced an ADR, of which eight (16%) were local infusion site reactions and 43 (86%) were systemic reactions (n = 1 experienced both a local and a systemic reaction) ( Fig. 1 ). Treatment was ceased in 16/213 women (8%) due to intolerable adverse events. Of these 16 women, the infusion was recommenced on the same day for eight (50%) women of which one required infusion rate modification. For 2/16 (13%) other women, the infusion was recommenced on a separate day with premedication (cetirizine 10 mg administered in both women and additional hydrocortisone 250 mg intravenously in one) of which one had their infusion commenced at a slower rate. The 
Efficacy
Haemoglobin levels at delivery were available for 118 women (89%) in the IDA group and 73 women (90%) in the non-anaemic iron deficient group. Significant increases in haemoglobin were evident from prior to infusion until delivery among all anaemia severity levels (all P < 0.001), with the largest increase seen among women with severe anaemia (Fig. 2) . The presence of anaemia at delivery was 1% (n = 1/73), 7% (n = 2/30), 16% (n = 9/55) and 18%
(n = 6/33) among women with non-anaemic iron deficiency, mild anaemia, moderate anaemia and severe anaemia, respectively, who received IV IPM. 
Perinatal outcomes
One pregnancy in the IDA group resulted in a stillbirth, occurring three months following IV iron administration. The proportions of vaginal delivery (58% vs 50%), elective caesarean section (30% vs 35%) and emergency caesarean section (12% vs 16%), were similar between IDA and non-anaemia iron deficiency groups.
Similarly, prevalence of induction of labour (27% vs 32%), delivery by caesarean section (42% vs 51%), preterm birth (15% vs 16%), low birthweight (14% vs 9%) and postpartum haemorrhage (17% vs 16%) were similar between the IDA and non-anaemic iron defi- 
DISCUSSION
While the use of IV IPM was associated with significant improvements in haematological parameters, it was also associated with a much higher prevalence of adverse reactions than previously reported in the published literature, affecting approximately one in four women.
Overall, IV IPM was highly effective in raising haemoglobin levels by the time of delivery, resulting in resolution of anaemia in the vast majority of pregnant women. These findings are consistent with those from previously published studies. [4] [5] [6] Furthermore, it is evident that anaemia was resolved in a similar proportion of women who received a dose equal to or above recommended and those who received a dose below recommended. However, the degree of correction varied significantly as women who received a dose equal to or above recommended were more likely to have achieved a successful haemoglobin response at delivery than women given a dose lower than recommended. Consequently, the mean haemoglobin at delivery was also significantly different among the two groups. Low haemoglobin level at delivery is associated with increased perinatal morbidity and mortality; hence, adequate restoration of levels by the time of delivery is vital for optimum perinatal outcomes.
The prevalence of adverse reactions identified in this study (23.5%) was much higher than the 0-5% prevalence reported in the literature. When restricted to those considered moderatesevere, 32 women (15%) experienced an ADR requiring treatment cessation, rate modification or medical treatment of symptoms.
Singh et al. 5 reported no (0%) adverse reactions among a total of 50 exposed women; however, all women were pre-treated with 25 mg of intramuscular promethazine. Similarly, Sogbanmu maltose, which has been increasingly studied in pregnancy, does not require a test dose, and has been associated with a much lower risk of ADRs.
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The high prevalence of use of IV IPM in the management of non-anaemic iron deficiency was unexpected, with no clinical studies to guide appropriate use of IV iron for this indication. Total number of women experiencing an ADR 50 † †Total number of reactions experienced do not add up to the total number of women as some may have experienced more than one adverse drug reaction.
F I G U R E 2 Mean (±SD) haemoglobin change across pregnancy according to anaemia severity at the time of intravenous iron polymaltose infusion.
There is evidence that low iron stores in early pregnancy has a negative impact on pregnancy outcomes, with babies of women with non-anaemic iron deficiency weighing on average 192 g less than those of women with normal iron stores. This study has a number of strengths. With a total of 213 women, this is the largest study evaluating the use of IV IPM in pregnancy, compared to the cumulative total of 164 women included in previous publications. [4] [5] [6] Case notes for 100% of women identified as being dispensed IV IPM were reviewed and a variety of resources were used, including paper-based and electronic records, to capture as much complete data as possible on these women.
The limitations of this study are consistent with its retrospective nature. We were reliant on information obtainable from electronic or paper-based records and on tests ordered by clinicians as part of routine clinical care. For example, data
on haemoglobin values at delivery were obtainable in 90% of women compared with only 54% of women at 2-4 weeks following the IV iron infusion. Furthermore, iron studies were not available for 7% of women, making it impossible to determine if they were truly iron deficient. In addition, we did not have data regarding oral iron use following IV iron administration. Lastly, while the high prevalence of identified adverse events suggests that poor documentation was unlikely to be a significant issue, it is still possible that it represents an underestimate of total adverse reactions.
CONCLUSION
Intravenous IPM is effective in the treatment of iron deficiency anaemia in pregnancy; however, a higher rate of adverse drug reactions was noted (23.5%) in this study compared to that previously published in the literature. Despite success of treatment, a significant number of women received a dose lower than recommended by local clinical guidelines, with the dose received associated with significant differences in haematological response, highlighting the need of IV iron dose optimisation, especially in overweight or obese women.
